The content on this site is intended for healthcare professionals only
Dr Galsky talks to ecancertv at ESMO 2016 about promising results for immunotherapy in first and second line treatment of metastatic bladder cancer in two phase II trials.
Read the news story or watch an interview with Dr Balar for more.
CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
EAU 2024: Bladder cancer latest
OncoAlert round up July 28th to August 3rd, 2023
mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
